Capital World Investors
BCRX icon

Capital World Investors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Capital World Investors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,840,000
Closed -$8.14M – 518
2019
Q3 		$8.14M Buy
2,840,000
+2,498,679
+732% +$7.77M ﹤0.01% 480
2019
Q2 		$1.29M Buy
+341,321
New +$2.05M ﹤0.01% 513

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Capital World Investors's BCRX Position: Q4 2019 in Review

Capital World Investors sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2019, closing a stake of 2,840,000 shares — an estimated $8.14M sold.

Capital World Investors first reported a position in BCRX in Q2 2019 and held it in 2 quarters. The position peaked at $8.14M in Q3 2019. 136 funds tracked by Wall St. Rank hold BCRX as of Q4 2019.

  • Capital World Investors reported no remaining BioCryst Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Capital World Investors sold 2,840,000 BioCryst Pharmaceuticals shares in Q4 2019, an estimated $8.14M.
  • Capital World Investors first reported a position in BioCryst Pharmaceuticals in Q2 2019 and held it in 2 quarters.
  • Capital World Investors's BioCryst Pharmaceuticals position peaked at $8.14M in Q3 2019.
  • 136 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2019.

Based on Capital World Investors's 13F filing for Q4 2019, filed 18 Feb 2020.